NEBULA aims to create a ‘cells made in a box’ small-footprint, low human resource required cell expansion platform for GMP manufacturing of autologous cell-based therapies. The project aims to unlock personalized, affordable regenerative medicine treatments for the diverse U.S. population via an autonomous biomanufacturing system scaling the production of personalized induced pluripotent stem cells (iPSCs). If successful, the project can lay the foundation for broader innovation and access to treatment for diseases like Parkinson’s, heart failure, spinal cord injury, and age-related macular degeneration, among other conditions, affecting nearly 30 million Americans. NEBULA aims to facilitate the research and development of personalized, affordable treatments, significantly reducing the national health burden of these conditions.